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Abstract: The purpose of this study was to evaluate whether the Unified Protocol (UP)—a mecha-
nistically transdiagnostic psychological treatment—provides benefit to individuals with a range of
trauma histories, psychological difficulties, and diagnostic comorbidity. Using data from a sequential
multiple-assignment randomized trial (SMART), this exploratory analysis included a sample of
69 community-recruited adults seeking outpatient mental health treatment. We examined reductions
in anxiety and depressive symptoms and changes in aversive and avoidant reactions to intense
emotions—the UP’s putative mechanism—first by comparing individuals with and without trauma
histories and then specifically among participants with PTSD. Findings suggest that the UP may lead
to similar improvements in clinical diagnostic severity, anxiety, and depression among patients with
trauma exposure as those without trauma exposure. Roughly half of participants with PTSD demon-
strated reductions in PTSD clinical severity, anxiety, depression, and distress aversion, suggesting the
UP may be an efficacious treatment for people with PTSD and comorbid conditions.
Keywords: posttraumatic stress disorder; trauma; transdiagnostic; cognitive-behavioral therapy
1. Introduction
Most adults will experience at least one potentially traumatic event involving exposure
to actual or threatened death, serious injury, or sexual violence in their lifetime [1,2].
Although many individuals recover from the psychological effects of trauma within weeks
or months, some experience debilitating and prolonged distress [3]. Posttraumatic stress
disorder (PTSD) occurs when an individual exhibits persistent re-experiencing symptoms,
efforts to avoid trauma reminders, negative changes in mood and cognition, and heightened
arousal and reactivity [1]. However, trauma exposure is also associated with a range of
mood and anxiety disorders beyond PTSD [4]. Diagnostic comorbidity is the rule, rather
than the exception, among individuals with trauma histories and is associated with high
levels of functional impairment and poor quality of life [5,6].
Evidence-based trauma-focused protocols (e.g., Cognitive Processing Therapy, Pro-
longed Exposure) are consistently recommended as the “gold standard” treatment ap-
proaches for PTSD [7]. Yet, there are several reasons why these protocols may not ade-
quately address the needs of trauma-exposed individuals. First, some studies suggest that
the efficacy of PTSD treatments may be compromised when diagnostic comorbidities or
persistent and intense negative emotions are present. For example, treatment response
may be hampered among individuals with primary diagnoses of PTSD and secondary
diagnoses of major depressive or generalized anxiety disorder [8,9], as well as emotions like
guilt, shame, or anger [9–11]. However, it should be noted that other studies suggest mood
and anxiety comorbidities do not moderate outcomes for trauma-focused treatments and
may even improve along with PTSD symptoms [7]. Second, evidence-based PTSD treat-
ments are rarely available to individuals seeking psychotherapy in community settings [12].
Frontline clinicians may not have the time or resources to participate in the specialized
training required for certification in evidence-based PTSD treatments or feel the need to
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provide such treatments if few patients on their caseloads report trauma-related symptoms.
Third, patients may not want to undergo PTSD treatments that focus explicitly on the
traumatic event or its consequences [13]. Thus, there is a need for alternative treatment
approaches that can be easily embedded within community clinics and address the needs
of individuals with an array of trauma-related psychopathology.
Transdiagnostic treatments specifically target shared psychological processes that
give rise to comorbid or co-occurring disorders [14,15]. One such treatment is the Unified
Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) [16]. The UP
includes five core skill modules that address aversive and avoidant reactions to intense
emotions, which are thought to maintain symptoms across emotional disorders [17]. The
UP is associated with large improvements in anxiety and depressive symptoms [18] com-
parable to single-disorder protocols [19]. Moreover, the UP can be adapted to meet the
needs of various patient populations and clinical contexts [20]. Mechanistically transdiag-
nostic treatments, like the UP, may provide a parsimonious and efficient way of treating
psychological difficulties among patients with complex comorbidity [21].
There is a strong theoretical and practical rationale for using mechanistically transdi-
agnostic treatments, like the UP, with trauma-exposed individuals [22–24]. Ample research
points to emotion regulation and tolerance as factors implicated in the onset and mainte-
nance of trauma-related psychopathology [25,26]. For example, individuals with poorer
perceived ability to regulate or tolerate intense emotions—and their corresponding physical
sensations—may be more likely to avoid trauma-related reminders, thus interfering with
the cue exposure necessary for normative recovery following traumatic events [25–27].
The UP provides skills to develop an approach-oriented and willing stance towards ex-
periencing emotions [28], which may counter avoidance of emotional, behavioral, and
physiological responses to trauma-related reminders and promote adaptive recovery. More-
over, the UP may provide an efficient and effective treatment alternative for patients who
are unwilling or unable to undergo a trauma-focused protocol.
To date, two studies have evaluated the use of the UP among trauma-exposed adults
with PTSD. Varkovitzky and colleagues [29] conducted an observational pilot study exam-
ining a 16-week group-based version of the UP embedded within a specialty PTSD clinic at
a Veterans Affairs hospital. PTSD and depressive symptoms significantly decreased, and
emotion regulation improved among the 52 veterans with military-related trauma who
completed both the pre- and post-treatment assessments. O’Donnell and colleagues [30] ex-
panded on this research in a randomized clinical trial comparing 10–14 individual sessions
of the UP to usual care among 43 adults with traumatic injuries recruited from a community
hospital. Compared to patients who received usual care, individuals who received the
UP showed significantly larger reductions in PTSD, anxiety, and depression at both the
post-treatment and 6-month follow-up assessments. Both studies provide preliminary
evidence that the UP is efficacious for individuals with PTSD.
Despite recent advances in using the UP for patients with PTSD from military or
traumatic injury exposure, a question remains as to whether the UP provides benefit
to individuals with a range of trauma histories, psychological difficulties, and diagnos-
tic comorbidity. Using data from a sequential multiple-assignment randomized trial
(SMART) [31], this exploratory analysis expands upon prior research by including a sample
of treatment-naive community-recruited adults seeking outpatient mental health treatment.
We examined reductions in anxiety and depressive symptoms and changes in aversive and
avoidant reactions to intense emotions—the UP’s putative mechanism—first by comparing
individuals with and without trauma histories and then specifically among participants
with PTSD. Explicit hypotheses were withheld for the present study.
2. Materials and Methods
2.1. Participants
Treatment-seeking individuals were recruited from the community to participate
in a SMART evaluating methods of personalizing the delivery of the UP. Individuals
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were eligible for the parent study if they met criteria for at least one of the following
Diagnostic and Statistical Manual-5 (DSM-5) disorders [1]: PTSD, generalized anxiety
disorder (GAD), obsessive-compulsive disorder (OCD), major depressive disorder (MDD),
panic disorder (PD), persistent depressive disorder (PDD), or social anxiety disorder (SAD).
Of the 165 individuals who completed a preliminary eligibility screen via phone, 72 were
excluded from participation due to having diagnoses that required clinical prioritization
(e.g., uncontrolled bipolar disorder within the past year [n = 6], substance use disorder
within the last 3 months [n = 1], current psychotic features [n = 7]), receiving five or more
sessions of CBT within the last five years (n = 9), recent discontinuation of psychotropic
medication (n = 1), being unwilling to pause current psychotherapy (n = 4), declining to
participate (n = 33), living out of state (n = 2), or not meeting inclusion criteria (n = 9).
Of the 93 individuals who completed the baseline assessment, 21 did not meet inclusion
criteria and two declined to participate.
Seventy participants were eligible for the parent study at the baseline assessment and
agreed to participate. Reports of trauma exposure were not available for one participant
due to a recording malfunction, so the final sample in the present analyses included
69 participants. Demographics and clinical characteristics are shown in Tables 1 and 2.
Most of the sample was female, white, heterosexual, college-educated, and single. One-
quarter of participants were on psychotropic medications. The most common principal
diagnoses (i.e., rated as most distressing/interfering) were GAD, MDD, and SAD. Nine
participants met diagnostic criteria for PTSD, and three had a principal diagnosis of PTSD.
On average, participants met criteria for three concurrent diagnoses at baseline.
Table 1. Baseline Demographic Characteristics.











Age (M, SD) 33.46 (12.51) 35.20 (12.45) 28.89 (11.78) 36.56 (12.19) 33.00 (12.59)
Gender
Female 46 (66.7) 34 (68.0) 12 (63.2) 5 (55.6) 41 (68.3)
Male 22 (31.9) 16 (32.0) 6 (31.6) 4 (44.4) 18 (30.0)
Genderqueer/Non-binary 1 (1.4) 0 (0.0) 1 (5.3) 0 (0.0) 1 (1.7)
Racial/Ethnic Background a
Caucasian 51 (73.9) 36 (72.0) 15 (78.9) 8 (88.9) 43 (71.7)
African-American 9 (13.0) 8 (16.0) 1 (5.3) 0 (0.0) 9 (15.0)
Arab/Middle-Eastern
American 2 (2.9) 2 (4.0) 0 (0.0) 0 (0.0) 2 (3.3)
East Asian 3 (4.3) 2 (4.0) 1 (5.3) 0 (0.0) 3 (5.0)
Latinx 2 (2.9) 1 (2.0) 1 (5.3) 1 (11.1) 1 (1.7)
South Asian 2 (2.9) 1 (2.0) 1 (5.3) 0 (0.0) 2 (3.3)
Heterosexual/Straight 51 (73.9) 41 (82.0) * 10 (52.6) 6 (66.7) 45 (75.0)
Bachelor’s Degree or Higher 41 (59.3) 32 (64.0) 9 (47.4) 5 (55.6) 36 (60.0)
Married 22 (31.9) 19 (38.0) 3 (15.8) 3 (33.3) 19 (31.7)
Note. Data are presented as number (percentage) of patients unless otherwise indicated. a Values may not sum to total in each column
because participants could select multiple racial/ethnic backgrounds. * p < 0.05.
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Table 2. Baseline Diagnostic Characteristics.













Current Psychotropic Medication 16 (23.2) 11 (22.9) 5 (29.4) 4 (44.4) 12 (21.4)
Principal Diagnoses a
Obsessive-Compulsive
Disorder 5 (7.2) 5 (10.0) 0 (0.0) 1 (11.1) 4 (6.7)
Social Anxiety Disorder 16 (23.2) 12 (24.0) 4 (21.1) 3 (33.3) 13 (21.7)
Generalized Anxiety Disorder 32 (46.4) 24 (48.0) 8 (42.1) 2 (22.2) 30 (50.0)
Panic Disorder 4 (5.8) 4 (8.0) 0 (0.0) 1 (11.1) 3 (5.0)
Agoraphobia 1 (1.4) 1 (2.0) 0 (0.0) 0 (0.0) 1 (1.7)
Major Depressive Disorder 19 (27.5) 13 (26.0) 6 (31.6) 3 (33.3) 16 (26.7)
Persistent Depressive Disorder 12 (17.4) 9 (18.0) 3 (15.8) 2 (22.2) 10 (16.7)
Acute Stress Disorder b 1 (1.4) 1 (2.0) - - 1 (1.7)
Posttraumatic Stress Disorder b 3 (4.3) 3 (6.0) - 3 (33.3) -
Diagnoses Met (M, SD) 3.04 (1.80) 3.28 (1.97) * 2.42 (1.07) 2.77 (1.47) 4.89 (2.71) *
Clinical Severity Rating (M, SD) 4.72 (1.00) 4.92 (0.94) ** 4.21 (0.98) 4.65 (0.95) 5.22 (1.20)
OASIS (M, SD) 9.18 (3.68) 9.84 (3.59) * 7.47 (3.42) 8.97 (3.44) 10.75 (5.15)
ODSIS (M, SD) 8.28 (5.09) 8.80 (5.10) 6.95 (4.95) 8.02 (5.06) 10.25 (5.18)
MEAQ-DA (M, SD) 47.26 (11.92) 47.32 (12.70) 47.10 (9.88) 47.18 (12.37) 47.78 (8.84)
Note. Data are presented as number (percentage) of patients unless otherwise indicated. a Values may not sum to total in each column
because participants could be diagnosed with multiple clinically significant diagnoses. b Participants were only asked diagnostic items
for ASD and PTSD if they reported a Criterion A trauma. ASD and PTSD are mutually exclusive diagnoses. OASIS = Overall Anxiety
Severity and Impairment Scale. ODSIS = Overall Depression Severity and Impairment Scale. MEAQ-DA = Multidimensional Experiential
Avoidance Questionnaire Distress Aversion subscale. * p < 0.05 ** p < 0.01.
2.2. Procedure
Informed consent was obtained before research activities began. All study procedures
were approved by the University of Kentucky Institutional Review Board (Protocol code:
53545). The pilot parent study (NCT04584879) used a two-stage SMART design to address
two primary aims: (1) examining the feasibility of personalizing UP skill module order and
(2) identifying proximal indicators of early treatment response. The present study included
the five core UP modules: Understanding Emotions (UE), Mindful Emotion Awareness
(MEA), Cognitive Flexibility (CF), Countering Emotional Behaviors (CEB), and Confronting
Physical Sensations (CPS). Weekly 45–60 min individual therapy sessions were delivered
by four study therapists certified in the UP.
The first-stage randomization occurred following the baseline assessment in which
participants were randomized to receive the UP skill modules in one of three sequencing
conditions: (1) a sequence that prioritized their personal strengths (capitalization condi-
tion); (2) a sequence that prioritized their personal deficits (compensation condition); or
(3) the standard module sequence described by Barlow et al. [16] (standard condition). To
sequence models in the capitalization and compensation conditions, self-report measures
corresponding to each UP skill were administered as part of the baseline assessment battery
(see summary of measures provided by Sauer-Zavala and colleagues [31]). Each partici-
pant’s raw scores on each measure were converted to z-scores and then rank-ordered from
highest (greatest strength) to lowest (greatest deficit). The second-stage randomization
occurred after the fifth therapy session, and patients were assigned to discontinue treatment
after the sixth session (brief condition) or to receive all 12 sessions (full condition).
Participants completed diagnostic assessments at three time points: (1) at baseline,
(2) prior to the second-stage randomization (i.e., before session 6), and (3) at the end
of the 12-week treatment window. Moreover, all participants completed a self-report
questionnaire battery before each therapy session and, for those in the brief condition,
each week between weeks 7–12. Additional information on procedures relevant to the
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main outcomes from the parent project, as well as a CONSORT flow chart can be found in
Sauer-Zavala et al. [31].
2.3. Measures
2.3.1. Diagnostic Assessment
The Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related
Neuropsychiatric Disorders (DIAMOND) [32] is a semi-structured diagnostic interview for
DSM-5 disorders. Trained graduate student assessors used the DIAMOND to determine
dimensional clinical severity ratings (CSR) of subjective distress and/or impairment for
each diagnostic category. CSR scores use a seven-point scale (1–7) with higher scores
reflecting greater distress/impairment. CSR scores > 3 represent clinically significant
distress/impairment and were used to define the presence of a given diagnosis. The
DIAMOND was administered at baseline to determine whether study inclusion/exclusion
were met and to record baseline clinical severity. The DIMOND was also administered
prior to the second-stage randomization (before week 6) and at the end of the 12-week
treatment window. Assessors demonstrated excellent reliability on categorical ratings of
primary diagnoses (Krippendorff’s αs: 0.91–1.00; median = 1.00) and dimensional severity
ratings (CSRs) of each disorder (Krippendorff’s αs: 0.83–1.00; median = 0.92).
The DIAMOND was also used to assess participants’ lifetime exposure to potentially
traumatic events. Assessors asked participants if they experienced any of the following:
war or combat; actual or threatened physical assault; actual or threatened sexual violence;
being kidnapped or held hostage; terrorist attack; being tortured or a prisoner of war;
natural or man-made disaster; serious motor vehicle accident; a sudden, terrible medical
event; or other traumatic experience. If an event was endorsed, participants were asked
to report if they experienced the event directly, witnessed or learned about the event,
or received repeated or extreme details of the event, which satisfies the definition of a
Criterion A trauma outlined in DSM-5 [1]. Only participants who endorsed Criterion A
trauma exposure were asked diagnostic items to determine the presence or absence of
acute stress disorder (ASD) or PTSD.
2.3.2. Self-Report
The Overall Anxiety Severity and Impairment Scale (OASIS) [33] and Overall Depres-
sion Severity and Impairment Scale (ODSIS) [34] are both 5-item self-report questionnaires
designed to measure anxiety and depression symptoms, respectively, over the prior week.
Total scores on the OASIS and ODSIS range from 0–20, with higher scores reflecting greater
symptom severity. The clinical cutoff score for each measure is 8. The OASIS and ODSIS
have exhibited good internal consistency, test-retest reliability, and convergent and dis-
criminant validity [33,34]. In the current sample, OASIS items demonstrated good internal
consistency (McDonald’s ω = 0.84) and ODSIS items demonstrated excellent internal
consistency (McDonald’sω = 0.94) at baseline.
The 13-item Distress Aversion subscale of the Multidimensional Experiential Avoid-
ance Questionnaire (MEAQ-DA) was used to assess the extent to which participants viewed
distress as unwelcome or intolerable [35]. Participants used a Likert-type scale from 1
(strongly disagree) to 6 (strongly agree), with higher scores reflecting a greater propensity
to experience aversive reactions to emotions—the UP’s putative mechanism. The MEAQ-
DA has demonstrated good internal consistency and strong convergent and discriminant
validity [35] in prior research. MEAQ-DA items demonstrated good internal consistency in
the present study at baseline (McDonald’sω = 0.89).
2.4. Data Analytic Approach
Means and standard deviations were used to summarize participants’ average scores
on continuous measures. Percentages were calculated to demonstrate participants’ expo-
sure to traumatic events. Chi-square tests were used to compare whether the proportion
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of participants exposed to traumatic events differed by treatment conditions (sequencing
or duration).
We assessed whether changes in anxiety, depression, and experiential avoidance
across the study period differed as a function of trauma exposure by developing two-level
hierarchal linear models (HLMs). HLMs can account for data that are nested within indi-
viduals (i.e., multiple time points per individual) and individuals with varying numbers
of observations. Predictors in the models included main effects of trauma exposure (not
exposed = 0, exposed = 1) and time. For models of CSR, time was operationalized as
assessment number (baseline = 1, before session 6 = 2, end-of-study period = 3). For models
of OASIS, ODSIS, and MEAQ-DA, time was operationalized as session number (1–12). To
examine whether the rate of change in outcomes of interest differed by trauma exposure
status, an interaction term between trauma and time (assessment or session number) was
included in all models. Dummy-coded indicator variables representing sequencing and
treatment duration conditions, and their interaction with time, were included as covariates.
Data from the post-treatment assessment and sessions 7–12 were excluded for participants
in the brief duration condition since they were not receiving treatment at those time points.
Including a random intercept led to non-convergence when modeling change in CSR scores
and, thus, only random slopes were included. All other models included both random
intercepts and random slopes. We used restricted maximum likelihood estimation and ap-
plied an unstructured covariance structure to the residuals because this structure led to the
best model fit as determined by Akaike Information Criterion. We used an intent-to-treat
sample by including all participants who completed a baseline assessment. Analyses were
conducted using SPSS version 28 [36] using the MIXED command. Study data collection
and management were performed via REDCap [37]. Significance was assessed at α =
0.05 and adjustments for multiple testing were not applied to the reported p-values. All
presented parameter estimates are unstandardized.
A power analysis for CSR scores examining interactions of between- and within-
person variables in a repeated measures design assuming power = 0.80, n = 69, 2 groups,
3 measurements, r = 0.50 correlation among repeated measures, and ε = 1.0 suggested we
had enough power to detect effects as small as f = 0.15 (i.e., small-to-medium sized effects
corresponding to d = 0.30). A power analysis for OASIS, ODSIS, and MEAQ-DA scores
examining interactions of between- and within-person variables in a repeated measures
design assuming power = 0.80, n = 69, 2 groups, 12 measurements, r = 0.60 correlation
among repeated measures, and ε = 1.0 suggested we had enough power to detect effects as
small as f = 0.09 (i.e., small sized effects corresponding to d = 0.18).
We examined the extent to which participants diagnosed with PTSD experienced
significant within-person reductions in anxiety, depression, and distress aversion by com-
puting 95% confidence intervals (CI) around observed change scores from pre- to post-
treatment to determine reliability of changes [38]. Jacobson and Truax’s [39] method was
used to calculate standard error of the difference (Sdiff), which reflects the difference be-
tween scores that is expected by chance variation alone on a given measure. Standard
deviations and internal consistency coefficients from the following psychometric stud-
ies were used to calculate the Sdiff: OASIS (SD = 3.05, Cronbach’s α = 0.80) [33], ODSIS
(SD = 5.04, Cronbach’s α = 0.94) [34], and MEAQ-DA (SD = 12.63, Cronbach’s α = 0.85) [35].
The Sdiff was then multiplied by 1.96 to create a 95% CI around each change score. If the
Sdiff 95% CI does not include zero, the observed change is considered reliable rather than
due to chance. Negative change scores indicate decreases on a given measure, and positive
change scores indicate increases.
3. Results
3.1. Trauma Exposure
The majority of participants in the sample (72.4%; n = 50) reported a history of trauma
exposure. There were similar proportions of participants with trauma exposure among
those who completed treatment and those who did not complete treatment, χ2 = 1.26,
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p = 0.74. Similarly, the proportion of trauma-exposed participants did not significantly
differ by module-sequencing condition, χ2 = 1.63, p = 0.44, or duration condition, χ2 = 0.66,
p = 0.42. As shown in Table 1, there was a larger proportion of people who identified
as heterosexual among those with trauma exposure than those without trauma exposure
(p = 0.01). However, there were no other significant differences in demographic variables
between groups. The most frequently reported traumatic events were serious motor
vehicle accidents, sudden, terrible medical events, and actual or threatened physical assault
or sexual violence (Table 3). Among participants with a lifetime history of traumatic
experiences, the average number of traumatic events reported was 1.52 (SD = 0.68), and
the maximum number of events was 4.
Table 3. Trauma Characteristics.
Type of Traumatic Event
Type of Trauma Exposure
Total
N = 69Experienced Witnessed Directly orLearned about
Received Repeated or
Extreme Details
n % n % n % n %
Exposure to war or combat 0 0 1 1.4 0 0 1 1.4
Actual or threatened physical assault 9 13.0 11 15.9 0 0 18 26.1
Actual or threatened sexual violence 9 13.0 5 7.2 0 0 14 20.3
Being kidnapped or held hostage 0 0 1 1.4 0 0 1 1.4
Terrorist attack 0 0 0 0 0 0 0 0.0
Being tortured or a prisoner of war 0 0 0 0 0 0 0 0.0
Natural or man-made disaster 1 1.4 0 0 0 0 1 1.4
Serious motor vehicle accident 12 17.4 10 14.5 0 0 20 29.0
A sudden, terrible medical event 6 8.7 15 21.7 0 0 18 26.1
Other traumatic event 0 0 1 1.4 2 2.9 3 4.3
Note. Values may not sum to total in each row because participants could report multiple types of exposure to the same traumatic event.
We examined the intraclass correlations (ICCs) of our measures of interest to determine
the proportion of variability in each measure attributable to between-person differences
and the proportion attributable to within-person fluctuations. As mentioned above, the
ICC for the CSR was unable to be calculated since including a random intercept term led
to model non-convergence. The ICC for the OASIS was 0.36, indicating that 36% of the
variability in this measure was due to between-person differences and 64% was due to
within-person fluctuations. By contrast, the ICCs for ODSIS (0.57) and MEAQ-DA (0.80)
indicated the majority of variability in these measures was between-persons.
Models were first run with time (i.e., assessment or session number) as the only
predictor. Participants demonstrated significant decreases on average across the study
period in CSR scores, B = −1.44, SE = 0.14, p < 0.001, 95% CI [−1.72, −1.16], OASIS scores,
B = −0.21, SE = 0.06, p = 0.002, 95% CI [−0.33, −0.08], ODSIS scores, B = −0.22, SE = 0.07,
p = 0.002, 95% CI [−0.35, −0.09], and MEAQ-DA scores, B = −1.04, SE = 0.18, p < 0.001,
95% CI [−1.39, −0.69]. After adding all other relevant predictors, neither treatment or-
der nor duration were significantly associated with changes in CSR, OASIS, ODSIS, or
MEAQ-DA scores (ps > 0.05), and so the interactions between condition and time were not
included in the models. Final models included time, trauma exposure, a time by trauma
exposure interaction term, sequencing condition, and duration condition as predictors.
Compared to participants without trauma histories, those exposed to potentially traumatic
events reported significantly higher baseline CSR, B = 0.68, SE = 0.27, p = 0.01, 95% CI
[0.14, 1.22], OASIS scores, B = 2.20, SE = 0.84, p = 0.01, 95% CI [0.51, 3.88], and ODSIS
scores, B = 2.74, SE = 1.14, p = 0.02, 95% CI [0.45, 5.02]. However, trauma exposure was not
significantly related to MEAQ-DA scores at baseline, B = −1.48, SE = 3.38, p = 0.66, 95% CI
[−8.24, 5.27]. The interactions between trauma and time were also not significant, suggest-
ing participants’ rate of change in CSR, B = −0.14, SE = 0.32, p = 0.67, 95% CI [−0.77, 0.50],
OASIS scores, B = −0.11, SE = 0.14, p = 0.44, 95% CI [−0.38, 0.17], ODSIS scores, B = −0.28,
SE = 0.14, p = 0.054, 95% CI [−0.57, 0.005], and MEAQ-DA scores, B = 0.26, SE = 0.39,
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p = 0.51, 95% CI [−0.53, 1.05], did not differ in magnitude between those with and without
trauma exposure.
3.2. Posttraumatic Stress Disorder
Nine participants received diagnoses of PTSD (>3 CSR) at baseline (Table 4). Three
participants had principal diagnoses of PTSD and the remaining six participants had
principal diagnoses of GAD, MDD, OCD, PD, or SAD. On average, participants with
PTSD met criteria for 4.89 total diagnoses (SD = 2.71). Seven participants diagnosed with
PTSD reported experiencing physical (n = 6) or sexual assault (n = 1). One participant
reported both physical and sexual assault exposure and one reported neither. On average,
participants with PTSD reported 2.22 (SD = 0.83) types of potentially traumatic experiences.
All patients with PTSD scored a 2 or above on CSR for GAD and/or MDD.
Table 4. Change in Anxiety, Depression, and Distress Aversion Among Participants with PTSD Diagnoses.
Case
PTSD CSR OASIS95% CI = CS ± 3.78
ODSIS
95% CI = CS ± 3.42
MEAQ-DA
95% CI = CS ± 13.78





Case 1 s,b 5 - 18 - - 19 - - 53 - -
Case 2 ca,f 4 5 9 10
1
(−2.78, 4.78) 8 10
2
(−1.42, 5.42) 53 53
0
(−13.78, 13.78)
Case 3 †,ca,b 6 2 11 1
−10 *
(−13.78, −6.22) 5 0
−5 *
(−8.42, −1.58) 38 46
8
(−5.78, 21.78)
Case 4 †,s,f 4 2 3 3
0
(−3.78, 3.78) 5 4
−1
(−4.42, 2.42) 33 19
−14 *
(−27.78, −0.22)
Case 5 co,f 6 2 18 5
−13 *
(−16.78, −9.22) 17 5
−12 *
(−15.42, −8.58) 48 34
−14 *
(−27.78, −0.22)
Case 6 †,co,f 4 3 7 5
−2
(−5.78, 1.78) 8 6
−2
(−1.42, 5.42) 51 46
−5
(−18.78, 8.78)
Case 7 s,b 3 1 11 5
−6 *
(−9.78, −2.22) 10 5
−5 *
(−8.42, −1.58) 44 27
−17 *
(−30.78, −3.22)
Case 8 co,b 3 2 9 5
−4 *
(−7.78, −0.22) 10 4
−6 *
(−9.42, −2.58) 47 46
−1
(−14.78, 12.78)
Case 9 s,f 4 2 12 ‡ 8
−4 *
(−7.78, −0.22) 12
‡ 7 −5 *(−8.42, −1.58) 63 40
−23 *
(−36.78, −9.22)
Note. Negative change scores indicate decreases on a given measure, and positive change scores indicate increases. The standard error
of the difference is listed at the top of each column and reflects the value used to calculate the 95% CIs around each raw change score.
CI = confidence interval; CS = change score; CSR = Clinical Severity Rating; OASIS = Overall Anxiety Severity and Interference Scale;
ODSIS = Overall Depression Severity and Interference Scale; MEAQ-DA = Multidimensional Experiential Avoidance Questionnaire Distress
Aversion subscale. b Brief duration condition. ca Capitalization sequencing condition. co Compensation sequencing condition. f Full
duration condition. s Standard sequencing condition. † Participant had a principal diagnosis of PTSD. ‡ Participant did not complete the
OASIS and ODSIS at the first assessment, so data collected at baseline were substituted. * Indicates statistically significant decrease.
Outcome data at the post-treatment assessment were not available for one partici-
pant. Overall, the UP led to improvements for most participants; six of eight participants
no longer met diagnostic criteria for PTSD at post-treatment (i.e., CSR scores < 3). On
average, the UP led to decreases in anxiety (Mdifference = −4.86, SD = 5.18), depression
(Mdifference = −4.14, SD = 4.45), and distress aversion (Mdifference = −8.25, SD = 10.39) from
pre- to post-treatment. Five participants demonstrated reliable reductions in anxiety and
depression, and four participants demonstrated reliable reductions in distress aversion
(Table 4).
4. Discussion
In this study, we examined whether the effects of a transdiagnostic treatment for
emotional disorders (i.e., the UP) differed between people with and without a history of
trauma exposure and whether this treatment would lead to significant improvements in
diagnostic, symptomatic, and mechanistic outcomes among those with PTSD. Despite
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people with a history of trauma exposure reporting greater diagnostic clinical severity, anx-
iety, and depression at baseline than those without such a history, we found no significant
differences in the rates of change on any outcome between groups. Further, the UP led
to significant decreases in anxiety, depression, and distress aversion for roughly half of
participants with PTSD.
In line with previous research [40], we found that participants with a history of trauma
exposure demonstrated more severe clinical presentations and reported more severe anxi-
ety and depression than participants without such a history at baseline. By contrast, these
groups did not significantly differ in their ratings of distress aversion [41]. Together, these
findings suggest that exposure to traumatic events may promote the development of more
severe clinical symptoms, but other factors (e.g., maladaptive self-appraisals [42]; type of
traumatic event [43]) may influence whether people develop or maintain greater aversions
to distress after trauma exposure. Given that these results are cross-sectional, based on ret-
rospective self-reported trauma exposure, and drawn from a treatment-seeking sample, we
encourage future researchers to replicate these findings to determine their generalizability.
Trauma exposure did not significantly moderate the rate of change in diagnostic,
symptom, or mechanistic outcomes. At the same time, the size of these differences varied
substantially. Given that the beta weight of the interaction of time and trauma exposure
represents the average difference in slopes between groups and the beta weight of time
represents the average slope among the non-trauma exposed group, comparing the size
of these beta weights can provide an indication of how different the slopes are. CSR
slopes only differed by 11% between groups, whereas OASIS slopes differed by 52%, and
ODSIS slopes differed by 127%. The direction of each interaction indicated that participants
with trauma exposure experienced steeper rates of change on all three measures. By
contrast, participants without trauma exposure experienced a 25% steeper rate of change
in distress aversion. Together, these results indicate that the UP leads to similar diagnostic,
clinical, and mechanistic improvements for patients regardless of trauma exposure, with
some preliminary evidence of greater improvement in depression and anxiety but less
improvement in distress aversion for patients with a trauma history. Our findings may
imply that the UP is similarly efficacious at reducing clinical symptoms for people with
and without trauma exposure but may act on a mechanism other than distress aversion
to do so. Alternatively, given that clinical symptoms, but not distress aversion, were
higher at baseline in the trauma-exposed group, these results may be due in part to
regression to the mean. It is also possible that distress aversion is more resistant to change
during treatment than clinical symptoms. We encourage future researchers to test these
hypotheses more specifically by evaluating session-to-session changes in distress aversion
as a potential mediator of clinical outcomes among a larger sample of people with and
without trauma exposure.
Finally, this study provides preliminary support for continued investigation of the UP
as a treatment for PTSD and comorbid conditions among trauma-exposed adults. Seven out
of eight participants with PTSD at baseline demonstrated decreases in the severity of their
PTSD diagnoses across treatment. Five participants demonstrated significant reductions in
anxiety, and six participants reported OASIS scores below the suggested clinical threshold.
Similarly, five participants demonstrated significant reductions in depression, and seven
participants reported ODSIS scores below the suggested clinical threshold. Finally, four
participants demonstrated significant reductions in distress aversion, three of whom also
reported significant reductions in anxiety and depression. These results provide prelim-
inary evidence for the generalizability of the UP for PTSD beyond those with military
or traumatic injury exposure. Our results further suggest the UP may be efficacious for
comorbid anxiety and depression among those presenting with primary PTSD, in line with
the transdiagnostic nature of this treatment protocol. To support this claim, we encourage
researchers to test the non-inferiority of the UP for PTSD compared to “gold standard”
trauma-focused treatments—similar to Barlow and colleagues’ [19] non-inferiority test of
the UP for anxiety disorders compared to single-disorder anxiety treatment protocols—in a
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fully-powered randomized clinical trial among individuals with PTSD diagnoses from var-
ious traumatic event exposure. The UP may indeed work well to reduce clinical symptoms
among trauma-exposed adults without PTSD, whereas other treatment approaches may
be more appropriate when PTSD is present. Future research should be designed to test
this question by comparing the effectiveness of the UP among individuals without trauma
histories to trauma-exposed individuals with and without PTSD.
These results should be considered in light of the study’s limitations. First, our only
direct measures of PTSD were clinician-reported diagnostic and severity ratings. Although
we assessed PTSD criteria and severity at pre-, mid-, and post-treatment among those
diagnosed with PTSD at baseline, we encourage future researchers to improve upon these
assessments by using “gold-standard” diagnostic (e.g., the Clinician-Administered PTSD
Scale [44]) and more frequent self-report symptom assessments (e.g., the PTSD Checklist
for DSM-5 [45]) to specifically test how putative mechanisms in the UP directly impact
changes in PTSD symptomology. Second, trauma exposure was assessed retrospectively
and at the same time as diagnostic, clinical, and mechanistic outcomes, and so we cannot
determine the temporal precedence of these factors. Because we did not systematically
assess when trauma exposure occurred, we are unable to determine whether the chronicity
of trauma exposure is associated with greater comorbidity or differences in treatment
response. Third, our ability to generalize findings to the broader population is limited due
to the parent project’s exclusion criteria, the small number of participants with PTSD, and
the predominantly white and college-educated sample.
5. Conclusions
Our findings add to the burgeoning literature on the use of the UP as a possible
treatment for PTSD and comorbid conditions among trauma-exposed adults. Results
suggest the UP may lead to similar, if not larger, improvements in clinical severity, anxiety,
and depression among patients with trauma exposure compared to those without trauma
exposure. We found our results despite patients with trauma histories reporting higher
levels of these characteristics at baseline. There were no significant differences between
groups in the rate of improvement in distress aversion, suggesting that this mechanism
may also respond similarly to the UP among people with and without trauma exposure.
Finally, we found that roughly half of participants with PTSD demonstrated reductions in
PTSD clinical severity, anxiety, depression, and distress aversion, highlighting the potential
of the UP as an efficacious treatment for people with PTSD and comorbid conditions.
Author Contributions: Conceptualization, C.O.H., C.B., M.W.S., S.S.-Z.; Methodology, M.W.S.,
S.S.-Z.; Formal Analysis, C.O.H.; Data Curation, C.O.H., M.W.S., S.S.-Z.; Writing—Original Draft
Preparation, C.O.H., M.W.S., C.B., S.S.-Z.; Writing—Review & Editing, C.O.H., M.W.S., S.S.-Z.;
Visualization, C.O.H.; Project Administration, M.W.S., S.S.-Z.; Funding Acquisition, C.O.H. All
authors have read and agreed to the published version of the manuscript.
Funding: Effort on this project was supported by the National Institute on Drug Abuse (T32
DA035200) through the National Institutes of Health (NIH). This publication’s contents are solely the
responsibility of the authors and do not necessarily represent the official views of NIH.
Institutional Review Board Statement: The study was conducted according to the guidelines of
the Declaration of Helsinki and approved by the Institutional Review Board of the University of
Kentucky (Protocol code: 53545; Approval: 7 August 2021).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: Raw data are available upon request. Syntax files for the primary out-
comes are located on Open Science Framework (https://osf.io/xrv8k/) (accessed on 8 November 2021).
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Environ. Res. Public Health 2021, 18, 11729 11 of 12
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®); American Psychiatric Publishing:
Washington, DC, USA, 2013.
2. Kessler, R.C.; Aguilar-Gaxiola, S.; Alonso, J.; Benjet, C.; Bromet, E.J.; Cardoso, G.; Degenhardt, L.; de Girolamo, G.; Dinolova, R.V.;
Ferry, F.; et al. Trauma and PTSD in the WHO world mental health surveys. Eur. J. Psychotraumatol. 2017, 8 (Suppl. 5), 1353383.
[CrossRef]
3. Chapman, C.; Mills, K.; Slade, T.; McFarlane, A.C.; Bryant, R.A.; Creamer, M.; Silove, D.; Teesson, M. Remission from post-
traumatic stress disorder in the general population. Psychol. Med. 2012, 42, 1695–1703. [CrossRef] [PubMed]
4. Bryant, R.A.; O’Donnell, M.L.; Creamer, M.; McFarlane, A.C.; Clark, C.R.; Silove, D. The psychiatric sequelae of traumatic injury.
Am. J. Psychiatry 2010, 167, 312–320. [CrossRef] [PubMed]
5. Gallagher, M.W.; Brown, T.A. Bayesian analysis of current and lifetime comorbidity rates of mood and anxiety disorders in
individuals with posttraumatic stress disorder. J. Psychopathol. Behav. Assess. 2015, 37, 60–66. [CrossRef] [PubMed]
6. Lockwood, E.; Forbes, D. Posttraumatic stress disorder and comorbidity: Untangling the Gordian knot. Psychol. Inj. Law 2014, 7,
108–121. [CrossRef]
7. Forbes, D.; Bisson, J.I.; Monson, C.M.; Berliner, L. Effective Treatments for PTSD: Practice Guidelines from the International Society of
Traumatic Stress Studies, 3rd ed.; Guilford Publications: New York, NY, USA, 2020; pp. 188–233.
8. Murphy, D.; Smith, K.V. Treatment efficacy for veterans with posttraumatic stress disorder: Latent class trajectories of treatment
response and their predictors. J. Trauma Stress 2018, 31, 753–763. [CrossRef]
9. Phelps, A.; Steel, Z.; Metcalf, O.; Alkemade, N.; Kerr, K.; O’Donnell, M.; Nursey, J.; Cooper, J.; Howard, A.; Armstrong, R. Key
patterns and predictors of response to treatment for military veterans with posttraumatic stress disorder: A growth mixture
modelling approach. Psychol. Med. 2018, 48, 95–103. [CrossRef]
10. Forbes, D.; Parslow, R.; Creamer, M.; Allen, N.; McHugh, T.; Hopwood, M. Mechanisms of anger and treatment outcome in
combat veterans with posttraumatic stress disorder. J. Trauma Stress 2008, 21, 142–149. [CrossRef]
11. Saraiya, T.; Lopez-Castro, T. Ashamed and afraid: A scoping review of the role of shame in post-traumatic stress disorder (PTSD).
J. Clin. Med. 2016, 5, 94. [CrossRef]
12. Riggs, D.S.; Paxton Willing, M.M.; Mailonee, S.; Rosen, C.; Wiltsey Stirman, S.; Dorsey, S. Training and implementation of
evidence-based psychotherapies for PTSD. In Effective Treatments for PTSD: Practice Guidelines from the International Society of
Traumatic Stress Studies, 3rd ed.; Forbes, D., Bisson, J.I., Monson, C.M., Berliner, L., Eds.; Guilford Publications: New York, NY,
USA, 2020; pp. 469–491.
13. Gutner, C.A.; Pedersen, E.R.; Drummond, S.P. Going direct to the consumer: Examining treatment preferences for veterans with
insomnia, PTSD, and depression. Psychiatry Res. 2018, 263, 108–114. [CrossRef]
14. Sauer-Zavala, S.; Gutner, C.A.; Farchione, T.J.; Boettcher, H.T.; Bullis, J.R.; Barlow, D.H. Current definitions of “transdiagnostic” in
treatment development: A search for consensus. Behav. Ther. 2017, 48, 128–138. [CrossRef] [PubMed]
15. Southward, M.W.; Sauer-Zavala, S. Experimental manipulations to test theory-driven mechanisms of cognitive behavior therapy.
Front. Psychiatry 2020, 11, 603009. [CrossRef]
16. Barlow, D.H.; Sauer-Zavala, S.; Farchione, T.; Murray Latin, H.; Ellard, K.K.; Bullis, J.R.; Bentley, K.H.; Boettcher, H.T.; Cassiello-
Robbins, C. Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders; Oxford University Press: New York, NY,
USA, 2018.
17. Wilamowska, Z.A.; Thompson-Hollands, J.; Fairholme, C.P.; Ellard, K.K.; Farchione, T.J.; Barlow, D.H. Conceptual background,
development, and preliminary data from the unified protocol for transdiagnostic treatment of emotional disorders. Depress.
Anxiety 2010, 27, 882–890. [CrossRef] [PubMed]
18. Sakiris, N.; Berle, D. A systematic review and meta-analysis of the Unified Protocol as a transdiagnostic emotion regulation based
intervention. Clin. Psychol. Rev. 2019, 72, 101751. [CrossRef]
19. Barlow, D.H.; Farchione, T.J.; Bullis, J.R.; Gallagher, M.W.; Murray-Latin, H.; Sauer-Zavala, S.; Bentley, K.H.; Thompson-Hollands,
J.; Conklin, L.R.; Boswell, J.F.; et al. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with
diagnosis-specific protocols for anxiety disorders: A randomized clinical trial. JAMA Psychiatry 2017, 74, 875–884. [CrossRef]
[PubMed]
20. Cassiello-Robbins, C.; Southward, M.W.; Tirpak, J.W.; Sauer-Zavala, S. A systematic review of Unified Protocol applications
with adult populations: Facilitating widespread dissemination via adaptability. Clin. Psychol. Rev. 2020, 78, 101852. [CrossRef]
[PubMed]
21. Southward, M.W.; Cassiello-Robbins, C.; Zelkowitz, R.L.; Rosenthal, M.Z. Navigating the new landscape of value-based care: An
example of increasing access, improving quality, and reducing costs using the Unified Protocol. Behav. Ther. 2020, 43, 134–137.
22. Gallagher, M.W. Transdiagnostic mechanisms of change and cognitive-behavioral treatments for PTSD. Curr. Opin. Psychol. 2017,
14, 90–95. [CrossRef]
23. Gutner, C.A.; Galovski, T.; Bovin, M.J.; Schnurr, P.P. Emergence of transdiagnostic treatments for PTSD and posttraumatic distress.
Curr. Psychiatry Rep. 2016, 18, 95–102. [CrossRef]
24. Gutner, C.A.; Presseau, C. Dealing with complexity and comorbidity: Opportunity for transdiagnostic treatment for PTSD. Curr.
Treat. Options Psychiatry 2019, 6, 119–131. [CrossRef]
Int. J. Environ. Res. Public Health 2021, 18, 11729 12 of 12
25. Akbari, M.; Hosseini, Z.S.; Seydavi, M.; Zegel, M.; Zvolensky, M.J.; Vujanovic, A.A. Distress tolerance and posttraumatic stress
disorder: A systematic review and meta-analysis. Cogn. Behav. Ther. 2021, 1–30. Available online: https://pubmed.ncbi.nlm.nih.
gov/34279189/ (accessed on 8 November 2021).
26. Seligowski, A.V.; Lee, D.J.; Bardeen, J.R.; Orcutt, H.K. Emotion regulation and posttraumatic stress symptoms: A meta-analysis.
Cogn. Behav. Ther. 2015, 44, 87–102. [CrossRef]
27. Hood, C.O.; Jones, A.C.; Flores, J.; Badour, C.L.; Feldner, M.T. Distress tolerance interacts with peritraumatic emotions to predict
posttraumatic stress symptoms following sexual victimization. Traumatology 2020, 26, 396–404. [CrossRef]
28. Southward, M.W.; Sauer-Zavala, S. Dimensions of skill use in the unified protocol: Exploring unique effects on anxiety and
depression. J. Consult. Clin. Psychol. 2021. Advance online publication.
29. Varkovitzky, R.L.; Sherrill, A.M.; Reger, G.M. Effectiveness of the unified protocol for transdiagnostic treatment of emotional
disorders among veterans with posttraumatic stress disorder: A pilot study. Behav. Modify 2018, 42, 210–230. [CrossRef]
30. O’Donnell, M.L.; Lau, W.; Chisholm, K.; Agathos, J.; Little, J.; Terhaag, S.; Brand, R.; Putica, A.; Holmes, A.C.; Katona, L.A.; et al.
pilot study of the efficacy of the unified protocol for transdiagnostic treatment of emotional disorders in treating posttraumatic
psychopathology: A randomized controlled trial. J. Trauma. Stress 2021, 34, 563–574. [CrossRef]
31. Sauer-Zavala, S.; Southward, M.W.; Stumpp, N.E.; Semcho, S.A.; Hood, C.O.; Garlock, A.; Urs, A.; MacLean, D. A SMART
approach to personalized care: How to select and sequence skills in transdiagnostic CBT. 2021, Under review.
32. Tolin, D.F.; Gilliam, C.; Wootton, B.M.; Bowe, W.; Bragdon, L.B.; Davis, E.; Hannan, S.E.; Steinman, S.A.; Worden, B.; Hallion, L.S.
Psychometric properties of a structured diagnostic interview for DSM-5 Anxiety, Mood, and Obsessive-Compulsive and Related
Disorders. Assessment 2018, 25, 3–13. [CrossRef] [PubMed]
33. Norman, S.B.; Cissell, S.H.; Means-Christensen, A.J.; Stein, M.B. Development and validation of an Overall Anxiety Severity and
Impairment Scale (OASIS). Depress. Anxiety 2006, 23, 245–249. [CrossRef] [PubMed]
34. Bentley, K.H.; Gallagher, M.W.; Carl, J.R.; Barlow, D.H. Development and validation of the Overall Depression Severity and
Impairment Scale. Psychol. Assess. 2014, 26, 815–830. [CrossRef] [PubMed]
35. Gámez, W.; Chmielewski, M.; Kotov, R.; Ruggero, C.; Watson, D. Development of a measure of experiential avoidance: The
Multidimensional Experiential Avoidance Questionnaire. Psychol. Assess. 2011, 23, 692–713. [CrossRef]
36. IBM Corp. IBM SPSS Statistics for Windows, version 27.0; IBM Corp: Armonk, NY, USA, 2020.
37. Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap): A metadata-
driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009, 42,
377–381. [CrossRef]
38. Au, T.M.; Sauer-Zavala, S.; King, M.W.; Petrocchi, N.; Barlow, D.H.; Litz, B.T. Compassion-based therapy for trauma-related
shame and posttraumatic stress: Initial evaluation using a multiple baseline design. Behav. Ther. 2017, 48, 207–221. [CrossRef]
39. Jacobson, N.S.; Truax, P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.
J. Consult. Clin. Psychol. 1992, 59, 12–19. [CrossRef]
40. Norman, S.B.; Allard, C.B.; Trim, R.S.; Thorp, S.R.; Behrooznia, M.; Masino, T.T.; Stein, M.B. Psychometrics of the Overall Anxiety
Severity and Impairment Scale (OASIS) in a sample of women with and without trauma histories. Arch. Women’s Ment. Health
2013, 16, 123–129. [CrossRef] [PubMed]
41. Thompson, B.L.; Waltz, J. Mindfulness and experiential avoidance as predictors of posttraumatic stress disorder avoidance
symptom severity. J. Anxiety Disord. 2010, 24, 409–415. [CrossRef]
42. Bryant, R.A.; Guthrie, R.M. Maladaptive self-appraisals before trauma exposure predict posttraumatic stress disorder. J. Consult.
Clin. Psychol. 2007, 75, 812–815. [CrossRef]
43. Kessler, R.C.; Rose, S.; Koenen, K.C.; Karam, E.G.; Stang, P.E.; Stein, D.J.; Heeringa, S.G.; Hill, E.D.; Liberzon, I.; McLaughlin, K.A.;
et al. How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO
World Mental Health Surveys. World Psychiatry 2014, 13, 265–274. [CrossRef]
44. Weathers, F.W.; Bovin, M.J.; Lee, D.J.; Sloan, D.M.; Schnurr, P.P.; Kaloupek, D.G.; Keane, T.M.; Marx, B.P. The Clinician-
Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol.
Assess. 2018, 30, 383. [CrossRef]
45. Blevins, C.A.; Weathers, F.W.; Davis, M.T.; Witte, T.K.; Domino, J.L. The posttraumatic stress disorder checklist for DSM-5 (PCL-5):
Development and initial psychometric evaluation. J. Trauma. Stress 2015, 28, 489–498. [CrossRef] [PubMed]
